TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05139095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib CohortA
Description: Cohort A: Camrelizumab (200 mg q2w iv) concomitantly with apatinib (250 mg qd po) and EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\] every 2 weeks. For certain patients with high tumor burden, 1-2 cycles of low-dose chemotherapy (actinomycin D 500 ug and etoposide 100mg/m2, D1-3) will be administered, then followed by EMA/CO. The observation period is 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib Cohort B
Description: Cohort B: Camrelizumab (200 mg q3w iv) concomitantly with apatinib (250 mg qd po) and multi-drug chemotherapy. The multi-drug chemotherapy regimen will be chosen by the investigator (chemotherapy regimen: EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\]; or EMA/EP \[etoposide, methotrexate and actinomycin-D/etoposide, cisplatin\]; or FAEV \[floxuridine, actinomycin-D, etoposide, vincristine\]). The observation period is 21 days.
Study: NCT05505643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocare SlimLine Cryoprobe
Description: The Endocare(TM) SlimLine (TM) Cryoprobe is a single use, disposable device designed for use with Endocare Cryocare Surgical Systems. Endocare cryoprobes are designed to deliver cold temperatures for cryoablation using high-pressure argon gas circulated through the cryoprobe, followed by active thawing using helium gas.~The Cryocare CS Surgical System is intended for use in open, minimally invasive, or endoscopic surgical procedures in the areas of general surgery, urology, gynecology, oncology, neurology, dermatology, ENT, proctology, pulmonary surgery, and thoracic surgery. The system is designed to freeze/ablate tissue by the application of extreme cold temperatures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumpectomy
Description: Patients randomized to cryoablation who experience disease recurrence may undergo crossover to lumpectomy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumpectomy
Description: Patients randomized to cryoablation who experience disease recurrence may undergo crossover to lumpectomy.
Study: NCT05192278

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block
Description: The patients will do the procedure under fluoroscopic guidance. The patients were placed in prone position. After the identification of the T4 transverse process, the targeted injection site was anesthetized with 3-4 ml of 2% lidocaine. A 25-gauge spinal needle was advanced until it contacted the transverse process at the T4 level. Next, a solution of 1mL of methylprednisolone 40mg/mL with 7 mL of 0.25% bupivacaine and 2mL of nonionic contrast in 10 ml saline 0.9% (group A) and in 20 ml saline 0.9% (group B) will injected. Then another photo will be taken with the fluoroscopy to determine the level of spread in each group. After finished, the patients will transfer to the post-operative care unit and will monitored for any complication for one hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block
Description: The patients will do the procedure under fluoroscopic guidance. The patients were placed in prone position. After the identification of the T4 transverse process, the targeted injection site was anesthetized with 3-4 ml of 2% lidocaine. A 25-gauge spinal needle was advanced until it contacted the transverse process at the T4 level. Next, a solution of 1mL of methylprednisolone 40mg/mL with 7 mL of 0.25% bupivacaine and 2mL of nonionic contrast in 10 ml saline 0.9% (group A) and in 20 ml saline 0.9% (group B) will injected. Then another photo will be taken with the fluoroscopy to determine the level of spread in each group. After finished, the patients will transfer to the post-operative care unit and will monitored for any complication for one hour.
Study: NCT04940078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once weekly doses of semaglutide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. over 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide and semaglutide
Description: Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide and semaglutide
Description: Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe
Study: NCT05175508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all trans retinoic acid
Description: ATRA 20mg tid by po on days 1-21 of every cycle 28 days
Study: NCT04542369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)
Description: Inductive/neoadjuvant therapy: Tislelizumab + EP Maintenance/adjuvant therapy: Tislelizumab + EP
Study: NCT05578352

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Add oral hyppoglycemia drug
Description: Oral hypoglycemic drugs with insulin sensitization effect are added, reduce insulin dose according to blood glucose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Add GLP-1 receptor agonist
Description: Add GLP-1 receptor agonist and reduce insulin dose according to blood glucose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change insulin
Description: Change premix insulin to long-acting insulin
Study: NCT05104905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexmarilimab
Description: A single neoadjuvant dose will be administered prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexmarilimab
Description: A single neoadjuvant dose will be administered prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexmarilimab
Description: A single neoadjuvant dose will be administered prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexmarilimab
Description: A single neoadjuvant dose will be administered prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexmarilimab
Description: A single neoadjuvant dose will be administered prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexmarilimab
Description: A single neoadjuvant dose will be administered prior to surgery.
Study: NCT05582317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biodentine
Description: Tricalcium silicate, dicalcium silicate, calcium carbonate and oxide filler, iron oxide shade and zirconium oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biodentine
Description: Tricalcium silicate, dicalcium silicate, calcium carbonate and oxide filler, iron oxide shade and zirconium oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
Study: NCT06260696

Intervention type: OTHER
Intervention: No treatment is given
Description: No treatment is given

Intervention type: OTHER
Intervention: No treatment is given
Description: No treatment is given

Intervention type: OTHER
Intervention: No treatment is given
Description: No treatment is given

Intervention type: OTHER
Intervention: No treatment is given
Description: No treatment is given

Intervention type: OTHER
Intervention: No treatment is given
Description: No treatment is given
Study: NCT06076434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Effect of Different Pressure Periods on Bruising and Pain After Subcutaneous Heparin Injection Applied to the Upper Arm Region
Description: The injection site on the upper arm of each patient was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected into the tissue at a 90° angle with a 27 gauge needle. The heparin was injected in approximately 10 seconds without aspirating the syringe. After the injection, pressure was applied to the area with dry cotton for specified periods (10 second, 35 second and 60 second).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Effect of Different Pressure Periods on Bruising and Pain After Subcutaneous Heparin Injection Applied to the Upper Arm Region
Description: The injection site on the upper arm of each patient was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected into the tissue at a 90° angle with a 27 gauge needle. The heparin was injected in approximately 10 seconds without aspirating the syringe. After the injection, pressure was applied to the area with dry cotton for specified periods (10 second, 35 second and 60 second).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Effect of Different Pressure Periods on Bruising and Pain After Subcutaneous Heparin Injection Applied to the Upper Arm Region
Description: The injection site on the upper arm of each patient was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected into the tissue at a 90° angle with a 27 gauge needle. The heparin was injected in approximately 10 seconds without aspirating the syringe. After the injection, pressure was applied to the area with dry cotton for specified periods (10 second, 35 second and 60 second).
Study: NCT04744779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Office-based accommodative/vergence therapy and home reinforcement
Description: Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
Study: NCT05653739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Intervention
Description: MBSR is Mindfulness based intervention designed by Kabat-Zinn (1990) in order to deal with the stress and other psychological issues among individuals. This has been very effective intervention across different cultures . In this 8 week intervention participants will be given some home tasks to practice for at least 40 minutes a day.
Study: NCT06095375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Cohort A (Adjuvant/Maintenance Phase). The Adjuvant (Maintenance) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level-1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with adjuvant TMZ to evaluate the initial toxicity of regorafenib and TMZ Cohort B (Concomitant Phase) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level -1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with TMZ and RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Cohort A (Adjuvant/Maintenance Phase). The Adjuvant (Maintenance) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level-1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with adjuvant TMZ to evaluate the initial toxicity of regorafenib and TMZ Cohort B (Concomitant Phase) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level -1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with TMZ and RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Following a 3+3 design, in cohort A three patients will be administered temozolomide 150-200 mg/m2 for 5 consecutive days every 28 days until 6-12 cycles and regorafenib daily for 21 days, with a 1-week washout period at dose of 80 mg (level 1), 120 mg (level 2), or 160 mg (level 3) (regorafenib 40 mg- level -1). As a general rule, one cycle will last 28 days (day 1-28); however, in the event of treatment prolongation, the cycle period will be extended.~In cohort B,During concomitant therapy phase: temozolomide 75 mg/m2/die for 42 (max 49 days) consecutive days (concomitant with radiation therapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Following a 3+3 design, in cohort A three patients will be administered temozolomide 150-200 mg/m2 for 5 consecutive days every 28 days until 6-12 cycles and regorafenib daily for 21 days, with a 1-week washout period at dose of 80 mg (level 1), 120 mg (level 2), or 160 mg (level 3) (regorafenib 40 mg- level -1). As a general rule, one cycle will last 28 days (day 1-28); however, in the event of treatment prolongation, the cycle period will be extended.~In cohort B,During concomitant therapy phase: temozolomide 75 mg/m2/die for 42 (max 49 days) consecutive days (concomitant with radiation therapy).
Study: NCT05740436

Intervention type: OTHER
Intervention: Geriatric rehabilitation program based on CGA
Description: Geriatric rehabilitation program based on CGA will be performed under physicians tight control for 21 days and will include physical activity, psychological training, diet correction, adaptation measures, polypragmasia correction.

Intervention type: OTHER
Intervention: Geriatric rehabilitation program based on CGA
Description: Geriatric rehabilitation program based on CGA will be performed under physicians tight control for 21 days and will include physical activity, psychological training, diet correction, adaptation measures, polypragmasia correction.

Intervention type: OTHER
Intervention: Geriatric rehabilitation program based on CGA
Description: Geriatric rehabilitation program based on CGA will be performed under physicians tight control for 21 days and will include physical activity, psychological training, diet correction, adaptation measures, polypragmasia correction.
Study: NCT05190523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42 5 mg
Description: 5 mg of ASC42 tablets orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42 10 mg
Description: 2 x 5 mg of ASC42 tablets orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42 15 mg
Description: 15 mg of ASC42 tablets orally once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets orally once daily for 12 weeks.
Study: NCT05041114

Intervention type: DEVICE
Group type: OTHER
Intervention: Motor Neuroprosthesis
Description: Type of implantable brain computer interface
Study: NCT04883424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education Program Based on Health Belief Model
Description: After the application, increase in family support and decrease in blood sugar levels are expected in diabetic patients. Family members' diabetic attitudes are expected to increase.
Study: NCT04167917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-301
Description: oral hypomethylating agent
Study: NCT05976646

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects who are randomized to placebo will receive identical capsules to the test product at the same time periods noted above, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auvelity
Description: Orally-administered combination of 45 mg dextromethorphan with 105 mg Bupropion (trade name Auvelity). Auvelity will initially be administered orally once daily for three days. After 3 days on once daily AUVELITY, the participants will begin taking AUVELITY twice daily for 4 additional days as recommended in the FDA-approved prescribing information.
Study: NCT04964219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval.
Study: NCT06100744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection
Study: NCT05077969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 80 mg tablet, QID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg (initial dose), then 200 mg capsule, BID for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, QID for 14 days; capsule, BID for 5 days
Study: NCT04390282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Application-based support system
Description: All participants (experimental and control group) will be invited to a separate appointment at the vascular open clinic at baseline and after three months and measured regarding weight, blood pressure, Ankle Brachial Pressure Index, six minutes walking test and pain. To calculate the estimate 10-year risk of manifesting clinical cardiovascular disease, the Framingham Risk Score will be used. Further, a questionnaire will be answered at baseline and after three months containing the instruments, VascuQoL-6, Health Education Impact Questionnaire and Medication Adherence Report Scale-5.
Study: NCT06327919

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Description: multi-strain probiotics were used in this study. Each probiotic capsule contains Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus reuteri, Lactobacillus rhamnosus, magnesium stearate and maltodextrin. 1.8 × 109 CFU / capsule. 2 capsules per day, for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: The placebo capsule contains 300 mg of starch. 2 capsules per day, for 12 weeks
Study: NCT05044897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: administration weekly by intravenous infusion（QW）.
Study: NCT05530525

Intervention type: DIAGNOSTIC_TEST
Intervention: The Computerized Adaptive Testing system of the Functional Assessment of Stroke
Description: The Computerized Adaptive Testing system of the Functional Assessment of Stroke comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper limb, 11 items from the Fugl-Meyer Assessment-Lower limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. Results are automatically reported as Rasch scores (i.e., the minimum and maximum values are negative and positive infinity, respectively). A higher score indicates greater physical functions.

Intervention type: DIAGNOSTIC_TEST
Intervention: The Barthel Index
Description: The Barthel Index has 10 items, and the total score ranges from 0 to 100. Higher score indicates less disability on activity of daily living functions.

Intervention type: DIAGNOSTIC_TEST
Intervention: The National Institutes of Health Stroke Scale
Description: The National Institutes of Health Stroke Scale comprises 11 items and was used to monitor the severity in the patients with stroke. The total score ranges from 0 to 42, with a higher score indicating greater severity. A National Institutes of Health Stroke Scale score of 1-5 indicates mild severity; 6-14, mild to moderate severity; 15-24, severe severity; and equal to or greater than 25, very severe severity.
Study: NCT06491953

Intervention type: DRUG
Intervention: SGLT-2 inhibitors
Description: SGLT-2 inhibitors use or not use； the duration of SGLT-2 inhibitors use
Study: NCT06655974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-related social needs decision support system
Description: The health-related social needs decision support system uses machine learning models to make recommendations for screening to ED providers and staff during patient visits.
Study: NCT06600711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: 5 mL suspension (100 mg), 2x/day for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical in consistency, appearance, and taste to nitazoxanide suspension. 5 mL suspension given 2x/day for 3 days